Immunotoxins in the therapy of cancer: from bench to clinic.
This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.
Ghetie
V
V
Department of Microbiology, University of Texas Southwestern Medical Center at Dallas 75235.
Vitetta
E
E
D000818:Animals; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy
D000922:Immunotoxins